A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45)

ATHENA (ClinicalTrials.gov identifier: NCT03522246) was designed to evaluate rucaparib first-line maintenance treatment in a broad patient population, including those without or (BRCA) mutations or other evidence of homologous recombination deficiency (HRD), or high-risk clinical characteristics suc...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of clinical oncology 2022-12, Vol.40 (34), p.3952-3964
Hauptverfasser: Monk, Bradley J, Parkinson, Christine, Lim, Myong Cheol, O'Malley, David M, Oaknin, Ana, Wilson, Michelle K, Coleman, Robert L, Lorusso, Domenica, Bessette, Paul, Ghamande, Sharad, Christopoulou, Athina, Provencher, Diane, Prendergast, Emily, Demirkiran, Fuat, Mikheeva, Olga, Yeku, Oladapo, Chudecka-Glaz, Anita, Schenker, Michael, Littell, Ramey D, Safra, Tamar, Chou, Hung-Hsueh, Morgan, Mark A, Drochýtek, Vít, Barlin, Joyce N, Van Gorp, Toon, Ueland, Fred, Lindahl, Gabriel, Anderson, Charles, Collins, Dearbhaile C, Moore, Kathleen, Marme, Frederik, Westin, Shannon N, McNeish, Iain A, Shih, Danny, Lin, Kevin K, Goble, Sandra, Hume, Stephanie, Fujiwara, Keiichi, Kristeleit, Rebecca S
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:ATHENA (ClinicalTrials.gov identifier: NCT03522246) was designed to evaluate rucaparib first-line maintenance treatment in a broad patient population, including those without or (BRCA) mutations or other evidence of homologous recombination deficiency (HRD), or high-risk clinical characteristics such as residual disease. We report the results from the ATHENA-MONO comparison of rucaparib versus placebo. Patients with stage III-IV high-grade ovarian cancer undergoing surgical cytoreduction (R0/complete resection permitted) and responding to first-line platinum-doublet chemotherapy were randomly assigned 4:1 to oral rucaparib 600 mg twice a day or placebo. Stratification factors were HRD test status, residual disease after chemotherapy, and timing of surgery. The primary end point of investigator-assessed progression-free survival was assessed in a step-down procedure, first in the HRD population (BRCA-mutant or BRCA wild-type/loss of heterozygosity high tumor), and then in the intent-to-treat population. As of March 23, 2022 (data cutoff), 427 and 111 patients were randomly assigned to rucaparib or placebo, respectively (HRD population: 185 49). Median progression-free survival (95% CI) was 28.7 months (23.0 to not reached) with rucaparib versus 11.3 months (9.1 to 22.1) with placebo in the HRD population (log-rank = .0004; hazard ratio [HR], 0.47; 95% CI, 0.31 to 0.72); 20.2 months (15.2 to 24.7) versus 9.2 months (8.3 to 12.2) in the intent-to-treat population (log-rank < .0001; HR, 0.52; 95% CI, 0.40 to 0.68); and 12.1 months (11.1 to 17.7) versus 9.1 months (4.0 to 12.2) in the HRD-negative population (HR, 0.65; 95% CI, 0.45 to 0.95). The most common grade ≥ 3 treatment-emergent adverse events were anemia (rucaparib, 28.7% placebo, 0%) and neutropenia (14.6% 0.9%). Rucaparib monotherapy is effective as first-line maintenance, conferring significant benefit versus placebo in patients with advanced ovarian cancer with and without HRD.
ISSN:0732-183X
1527-7755
1527-7755
DOI:10.1200/JCO.22.01003